CMV

Prophylactic letermovir significantly reduces cytomegalovirus infection after transplantation

January 01, 2018

Compared to placebo, letermovir prophylaxis significantly decreased the incidence of cytomegalovirus (CMV) infection through 24 weeks following hematopoietic stem cell transplantation (HSCT).